EIF2AK4 and plasma cell myeloma: This analysis revealed that treatment with GCN2iB has anti-myeloma activity, but induced a range of responses in HMCLs (Fig. 6c), which we hypothesized may correlate with differences in basal ISR-GCN2 pathway activation.